In vitro study of the effect of moisturizer 0921-F dan 0921-G on gene expression related to inflammation, nerve sedation and skin barrier

Abstract

Within the last few decades, sensitive skin has become a concern in 71% of the population (Chen et al., 2020). This condition is usually characterized by unpleasant feelings to the skin, including stinging, burning, and itching sensations and is usually triggered by environmental factors such as sun exposure and pollution or the presence of irritating substances in cosmetic products (e.g., AHA, alcohol, fragrances) (Diehl, 2018; Duarte et al., 2017). Although the pathophysiology of sensitive skin is not yet well understood, sensitive skin is currently thought to be the result of the decrease in stratum corneum thickness, which is the outer layer of the skin, and/or the dysfunction of neural activities in the skin. These two conditions will further trigger a series of inflammation which will worsen sensitive skin symptoms (Talagas & Misery, 2019). Currently, various treatments have been developed to treat sensitive skin. One of the well-known treatments is the use of emollient cream or moisturizer. Moisturizer is mentioned to be able to support skin barrier enhancement while reducing skin inflammation in subjects with higher skin sensitivity, which leads to the promising potential of moisturizer development that is targeted for sensitive skin (Baldwin, Santoro, Lachmann, & Teissedre, 2019). This study aims to evaluate a sensitive skin moisturizer (Moisturizer-0921-F) along with its base and active pharmaceutical ingredients (API) for their capability in improving skin barriers without eliciting neurological and skin inflammation.